title: A rare case of imatinib-induced erythroderma.
abstract: Imatinib, a specific tyrosine kinase inhibitor is a newer anticancer agent, which has shown excellent efficacy in managing chronic myeloid leukemia. It is generally well tolerated with few side effects. Most commonly reported adverse events are maculopapular eruptions and periorbital edema. Severe adverse reactions are seen in 5% of patients. Exfoliative dermatitis has been very rarely reported with this drug. We report a case of a 52-year-old male who initially presented with a maculopapular rash and developed erythroderma on continuation of the drug.
authors.affiliation: Department of Dermatology, Command Hospital, Pune, Maharashtra, India.
authors.forename: Rajesh
authors.initials: R
authors.lastname: Verma
authors.affiliation: Department of Dermatology, Command Hospital, Pune, Maharashtra, India.
authors.forename: Biju
authors.initials: B
authors.lastname: Vasudevan
authors.affiliation: Department of Dermatology, Command Hospital, Pune, Maharashtra, India.
authors.forename: Vijendran
authors.initials: V
authors.lastname: Pragasam
authors.affiliation: Department of Dermatology, Command Hospital, Pune, Maharashtra, India.
authors.forename: Shekhar
authors.initials: S
authors.lastname: Neema
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides / Q000009:adverse effects*; D003873:Dermatitis, Exfoliative / Q000139:chemically induced*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate
keywords: Adverse cutaneous drug reaction; Imatinib; erythroderma